{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T21:42:00Z","timestamp":1694382120972},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,5,1]]},"DOI":"10.1093\/ndt\/gfk031","type":"journal-article","created":{"date-parts":[[2006,1,10]],"date-time":"2006-01-10T01:13:06Z","timestamp":1136855586000},"page":"1395-1401","source":"Crossref","is-referenced-by-count":6,"title":["Adverse neuropsychiatric effects of cytomegalovirus prophylaxis with valaciclovir in renal transplant recipients"],"prefix":"10.1093","volume":"21","author":[{"given":"Vincent","family":"Das","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Noelle","family":"Peraldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Legendre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2006,1,9]]},"reference":[{"key":"key\n\t\t\t\t20171012210003_BIB1","doi-asserted-by":"crossref","unstructured":"Brennan DC. Cytomegalovirus in renal transplantation. J Am Soc Nephrol2001; 12: 848\u201355","DOI":"10.1681\/ASN.V124848"},{"key":"key\n\t\t\t\t20171012210003_BIB2","doi-asserted-by":"crossref","unstructured":"Lowance D, Neumayer HH, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med1999; 340: 1462\u201370","DOI":"10.1056\/NEJM199905133401903"},{"key":"key\n\t\t\t\t20171012210003_BIB3","doi-asserted-by":"crossref","unstructured":"Ormrod D, Scott LJ, Perry CM. Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections. Drugs2000; 59: 839\u201363","DOI":"10.2165\/00003495-200059040-00013"},{"key":"key\n\t\t\t\t20171012210003_BIB4","doi-asserted-by":"crossref","unstructured":"Linssen-Schuurmans CD, van Kan EJ, Feith GW, Uges DR. Neurotoxicity caused by valacyclovir in a patient on hemodialysis. Ther Drug Monit1998; 20: 385\u20136","DOI":"10.1097\/00007691-199808000-00005"},{"key":"key\n\t\t\t\t20171012210003_BIB5","unstructured":"ADRAC. Valaciclovir: renal impairment and neuropsychiatric reactions. Australian Adverse Drug Reactions Bulletin2000; 19: 7"},{"key":"key\n\t\t\t\t20171012210003_BIB6","unstructured":"Beau-Salinas F, Jonville-Bera AP, Bensouda L, Autret-Leca E. Neurotoxicity of valaciclovir (Zelitrex): increased risk for patients with chronic renal failure and for the elderly. Oral communication, 23\u00e8mes journ\u00e9es de pharmacovigilance (Joint meeting of the Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie and Pharmacological Societies of Brazil and Portugal) Rennes, April 2002. Abstract O28. Fundam Clin Pharmacol2002; 16: 373"},{"key":"key\n\t\t\t\t20171012210003_BIB7","doi-asserted-by":"crossref","unstructured":"Peyriere H, Branger B, Bengler C et al. Neurologic toxicity caused by zelitrex (valaciclovir) in 3 patients with renal failure. Is overdose associated with improvement of product bioavailability improvement? Rev Med Interne2001; 22: 297\u2013303","DOI":"10.1016\/S0248-8663(00)00332-5"},{"key":"key\n\t\t\t\t20171012210003_BIB8","doi-asserted-by":"crossref","unstructured":"Adair JC, Gold M, Bond RE. Acyclovir neurotoxicity: clinical experience and review of the literature. South Med J1994; 87: 1227\u201331","DOI":"10.1097\/00007611-199412000-00006"},{"key":"key\n\t\t\t\t20171012210003_BIB9","doi-asserted-by":"crossref","unstructured":"Ernst ME, Franey RJ. Acyclovir- and ganciclovir-induced neurotoxicity. Ann Pharmacother1998; 32: 111\u20133","DOI":"10.1345\/aph.17135"},{"key":"key\n\t\t\t\t20171012210003_BIB10","doi-asserted-by":"crossref","unstructured":"Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS. Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure. Am J Med1982; 73: 202\u20134","DOI":"10.1016\/0002-9343(82)90091-2"},{"key":"key\n\t\t\t\t20171012210003_BIB11","doi-asserted-by":"crossref","unstructured":"Gimenez F, Foeillet E, Bourdon O et al. Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects. Clin Pharmacokinet2004; 43: 685\u2013692","DOI":"10.2165\/00003088-200443100-00004"},{"key":"key\n\t\t\t\t20171012210003_BIB12","unstructured":"Hellden AD, Sawe J, Barkholt L, Svensson JO, Stahle L. High concentrations in serum of 9-Carboxymethoxymethylguanine (CMMG) in ESRD patients with Acyclovir-related neurotoxicity. 38th ICAAC. San Diego, California, USA, 1998"},{"key":"key\n\t\t\t\t20171012210003_BIB13","doi-asserted-by":"crossref","unstructured":"Haefeli WE, Schoenenberger RA, Weiss P, Ritz RF. Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose. Am J Med1993; 94: 212\u20135","DOI":"10.1016\/0002-9343(93)90186-S"},{"key":"key\n\t\t\t\t20171012210003_BIB14","doi-asserted-by":"crossref","unstructured":"Yango A, Morrisey P, Zanabli A et al. Comparative study of prophylactic oral ganciclovir and valacyclovir in high risk kidney transplant recipients. Nephrol Dial Transplant2003; 18: 809\u201313","DOI":"10.1093\/ndt\/gfg039"},{"key":"key\n\t\t\t\t20171012210003_BIB15","doi-asserted-by":"crossref","unstructured":"Winston DJ, Yeager AM, Chandrasekar PH et al. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis2003; 36: 749\u201358","DOI":"10.1086\/367836"},{"key":"key\n\t\t\t\t20171012210003_BIB16","doi-asserted-by":"crossref","unstructured":"Gabardi S, Magee CC, Baroletti SA et al. Efficacity and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis. Pharmacotherapy2004; 24: 1323\u201330","DOI":"10.1592\/phco.24.14.1323.43152"},{"key":"key\n\t\t\t\t20171012210003_BIB17","doi-asserted-by":"crossref","unstructured":"Limaye AP, Corey L, Koelle DM et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet2000; 356: 645\u20139","DOI":"10.1016\/S0140-6736(00)02607-6"},{"key":"key\n\t\t\t\t20171012210003_BIB18","doi-asserted-by":"crossref","unstructured":"Boivin G, Gilbert C, Gaudreau A et al. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J Infect Dis2001; 15: 1598\u2013602","DOI":"10.1086\/324672"},{"key":"key\n\t\t\t\t20171012210003_BIB19","doi-asserted-by":"crossref","unstructured":"Alain S, Hantz S, Scieux C et al. Detection of ganciclovir resistance after valacyclovir-prophylaxis in renal transplant recipients with active cytomegalovirus infection. J Med Virol2004; 73: 566\u201373","DOI":"10.1002\/jmv.20127"},{"key":"key\n\t\t\t\t20171012210003_BIB20","doi-asserted-by":"crossref","unstructured":"Reddy SP, Handa A, Tan L et al. Low-dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients. Transpl Int2003; 16: 726\u20139","DOI":"10.1007\/s00147-003-0612-4"},{"key":"key\n\t\t\t\t20171012210003_BIB21","doi-asserted-by":"crossref","unstructured":"Sund F, Wahlberg J, Eriksson BM. CMV disease in CMV mismatched renal transplant recipients with prophylactic low dose valaciclovir. J Clin Virol2001; 23: 107\u201311","DOI":"10.1016\/S1386-6532(01)00213-X"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/21\/5\/1395\/6900798\/gfk031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T12:15:22Z","timestamp":1626956122000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/ndt\/article\/21\/5\/1395\/1822115\/Adverse-neuropsychiatric-effects-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,9]]},"references-count":21,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2006,1,9]]},"published-print":{"date-parts":[[2006,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfk031","relation":{},"ISSN":["1460-2385","0931-0509"],"issn-type":[{"value":"1460-2385","type":"electronic"},{"value":"0931-0509","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,5]]},"published":{"date-parts":[[2006,1,9]]}}}